ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

FUM Futura Medical Plc

36.80
2.80 (8.24%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  2.80 8.24% 36.80 36.60 37.30 37.30 35.00 35.00 753,383 16:35:27
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -5.85M -0.0194 -18.81 109.76M
Futura Medical Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker FUM. The last closing price for Futura Medical was 34p. Over the last year, Futura Medical shares have traded in a share price range of 24.10p to 67.00p.

Futura Medical currently has 300,712,293 shares in issue. The market capitalisation of Futura Medical is £109.76 million. Futura Medical has a price to earnings ratio (PE ratio) of -18.81.

Futura Medical Share Discussion Threads

Showing 15326 to 15333 of 21475 messages
Chat Pages: Latest  619  618  617  616  615  614  613  612  611  610  609  608  Older
DateSubjectAuthorDiscuss
16/12/2022
23:24
LiarBO, you're such a bad liar. Diddums.
petroc
16/12/2022
22:04
Diddums, LiarBO
petroc
16/12/2022
21:35
Diddums, LiarBO.
petroc
16/12/2022
20:39
A placebo is anything that seems to be a "real" medical treatment -- but isn't. It could be a pill, a shot, or some other type of "fake" treatment. What all placebos have in common is that they do not contain an active substance meant to affect health.



The Placebo Effect: How Important Is It in ED Treatment?


All Futura have done with MED3000 is open the door for Reckitt to sell similar lubricants/arousal gels as medical device placebo treatments for ED. And report Med3000 to the ASA, FTC etc for being misleading if it doesn’t inform consumers that MED3000 itself has no proven effect in ED beyond a placebo. As it has no proven efficacy in an adequate placebo controlled study or even against any standard cooling lubricant/arousal gels in an ED study.



‘You are the active ingredient’

Even the analysis on market forecasts knows Reckitt who is the market leader in lubricants will be only one to gain from marketing lubricants as placebo treatments for Erectile Dysfunction




Reckitt Benckiser was the defined leader and the ultimate four Personal lubricant vendors with leading brands such as Durex Play and K-Y Jelly.

KEY GROWTH FACTORS

Increasing prevalence of erectile dysfunction

9 Market Growth Enablers
9.1 Increasing Prevalence of Erectile Dysfunction

lbo
16/12/2022
20:30
Trinity Research even openly admitted the hypothesised effects ‘believed’ to be happening by Futura are ‘disputed’. Trinity admitted no mechanism of action has to be even shown to get a medical device approved. But it does need to be shown and proven to substantiate its marketing claims or fall foul of the FTC, ASA and the Courts.

Trinity research:

Presumably the effect is comparable to the cold-induced vasodilation (CIVD) that occurs with extremities such as toes and fingers. Despite being a well-known effect, the mechanisms of CIVD are still disputed, but the pathways involved could well be similar. Interestingly, the precise mechanism of action does not need to be elucidated for the regulators to be comfortable for a product to be approved as a medical device




A product that contemporary technology does not understand must establish that this magic, actually works. Proof is what separates an effect new to science from a swindle . . . . If a condition responds to treatment, then selling a placebo as if it had therapeutic effect directly injures the consumer

lbo
16/12/2022
19:31
Bias and Fraud

There are numerous biases in medical research that render evidence from such research systematically misleading. Some of these biases are exacerbated by conflicts of interest, including fantastic financial incentives. The most important biases in medical research include confirmation bias, design bias, analysis bias, and publication bias. Arguably, some forms of bias, such as publication bias, should be considered as fraud. The pervasiveness of bias in medical research justifies one of the premises of the master argument for medical nihilism. Medical research is malleable due to the many biases, and such malleability allows for the production of evidence that suggests medical interventions are effective, whether or not they are in fact effective.



The vanishing FAQ

Strangely, you won't find the above answers on the FAQ page currently. They seem to have been removed at some point in the past few days, but luckily I saved a copy from 19th March.

A placebo or not?

Something else has changed since the old version of Futura's FAQ. In the previous version,



PLO = Placebo (identical gel to MED2005 but without the active pharmaceutical ingredient glyceryl trinitrate)



After Phase III Failure, UK Firm Pushes Placebo to Treat Erectile Dysfunction



Expectations of having received the drug can be modulated if the subjective effects of a drug inform the individual that active medication has been administered and increase expectations of drug effects.

lbo
16/12/2022
19:29
So where did the ‘IDEA’ to market the topically applied placebo MED300 gel come from after MED failed its phase 3 drug trial?

You guessed it! From that TPR100 comparator that the brokers reference in old Futura note. Flexiseq gel yet another sham device (often referred to as TDT 064 in the scientific literature) used in the studies of IDEA-033

That 12 week clinical trial was deemed a failure when the investigational product IDEA-033 (Ketoprofen-in-vehicle) also failed to show a statistically significant benefit compared with the topical control, then known as TDT 064 ie FLEXISEQ.



‘˜with Johnson & Johnsons McNeill division having returned US rights to IDEA-033 recently’

lbo
16/12/2022
19:29
Diddums, LiarBO
petroc
Chat Pages: Latest  619  618  617  616  615  614  613  612  611  610  609  608  Older

Your Recent History

Delayed Upgrade Clock